Go Pro
→ BlackRock is hoarding it. JPMorgan is hoarding it. Do you own it? (From Awesomely) (Ad)tc pixel Free CTSO Stock Alerts

Cytosorbents (CTSO) Financials

Cytosorbents logo
$0.36 -0.01 (-2.54%)
Closing price 07/17/2026 04:00 PM Eastern
Extended Trading
$0.36 0.00 (0.00%)
As of 07/17/2026 04:46 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare
Annual Income Statements for Cytosorbents

Annual Income Statements for Cytosorbents

This table shows Cytosorbents' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -9.48 -12 -8.80 -17 -19 -7.84 -25 -33 -29 -21 -8.20
Consolidated Net Income / (Loss)		 -9.48 -12 -8.46 -17 -19 -7.84 -25 -33 -29 -21 -8.20
Net Income / (Loss) Continuing Operations		 -9.48 -12 -8.46 -17 -19 -7.84 -25 -33 -29 -21 -8.20
Total Pre-Tax Income 		-9.80 -12 -9.14 -18 -20 -8.96 -25 -34 -30 -22 -8.60
Total Operating Income		 -9.30 -11 -9.84 -16 -19 -10 -23 -32 -32 -16 -15
Total Gross Profit		 2.58 5.57 9.63 15 18 30 32 21 22 25 26
Total Revenue		 4.79 9.53 15 23 25 41 43 35 31 36 37
Operating Revenue		 4.78 9.53 15 23 25 41 43 35 31 36 37
Total Cost of Revenue		 2.21 3.95 5.52 7.49 7.36 11 11 14 9.13 11 11
Operating Cost of Revenue		 2.21 3.95 5.52 7.49 7.36 11 11 14 9.13 11 11
Total Operating Expenses		 12 17 19 31 37 40 55 52 54 41 41
Selling, General & Admin Expense		 8.01 13 16 23 24 32 38 37 38 34 36
Research & Development Expense		 3.87 4.07 3.22 7.72 12 8.81 16 15 16 7.61 5.09
Restructuring Charge		 - - - - - - - - - 0.00 0.51
Total Other Income / (Expense), net		 -0.50 -0.59 0.71 -2.25 -1.38 1.41 -2.55 -2.38 1.89 -5.96 6.15
Interest & Investment Income		 0.01 -0.23 -0.75 -1.46 -1.03 -1.20 0.03 0.13 -0.16 -1.40 -2.61
Other Income / (Expense), net		 -0.51 -0.36 1.45 -0.78 -0.35 2.61 -2.58 -2.52 2.05 -4.56 8.76
Income Tax Expense		 -0.32 -0.32 -0.68 -0.62 -1.09 -1.13 -0.74 -1.09 -0.81 -1.69 -0.40
Basic Earnings per Share		 ($0.38) ($0.46) ($0.32) ($0.56) ($0.60) ($0.20) ($0.57) ($0.75) ($0.65) ($0.38) ($0.13)
Weighted Average Basic Shares Outstanding		 24.89M 25.43M 27.61M 30.72M 32.26M 38.82M 43.36M 43.57M 44.66M 54.43M 62.23M
Diluted Earnings per Share		 ($0.38) ($0.46) ($0.32) ($0.56) ($0.60) ($0.20) ($0.57) ($0.75) ($0.65) ($0.38) ($0.13)
Weighted Average Diluted Shares Outstanding		 24.89M 25.43M 27.61M 30.72M 32.26M 38.82M 43.36M 43.57M 44.66M 54.43M 62.23M
Weighted Average Basic & Diluted Shares Outstanding		 24.89M 25.43M 27.61M 30.72M 32.26M 38.82M 43.51M 43.66M 54.29M 62.50M 62.70M

Quarterly Income Statements for Cytosorbents

This table shows Cytosorbents' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Income / (Loss) Attributable to Common Shareholders		 -9.19 -6.57 -6.09 -4.29 -2.77 -7.57 -1.48 1.95 -3.17 -5.50 -5.13
Consolidated Net Income / (Loss)		 -9.19 -6.57 -6.09 -4.29 -2.77 -7.57 -1.48 1.95 -3.17 -5.50 -5.13
Net Income / (Loss) Continuing Operations		 -9.19 -6.57 -6.09 -4.29 -2.77 -7.57 -1.48 1.95 -3.17 -5.50 -5.13
Total Pre-Tax Income 		-9.19 -7.39 -6.09 -4.29 -2.77 -9.26 -1.48 1.95 -3.57 -5.50 -5.13
Total Operating Income		 -7.35 -10 -4.66 -3.57 -4.83 -3.40 -3.89 -3.62 -2.86 -4.38 -3.04
Total Gross Profit		 5.61 4.87 6.87 6.50 5.26 6.25 6.21 6.81 6.67 6.80 6.13
Total Revenue		 8.81 3.40 8.99 8.84 8.61 9.15 8.73 9.62 9.49 9.23 8.86
Operating Revenue		 8.81 3.40 8.99 8.84 8.61 9.15 8.73 9.62 9.49 9.23 8.86
Total Cost of Revenue		 3.20 -1.47 2.12 2.34 3.36 2.90 2.52 2.80 2.82 2.43 2.73
Operating Cost of Revenue		 3.20 -1.47 2.12 2.34 3.36 2.90 2.52 2.80 2.82 2.43 2.73
Total Operating Expenses		 13 15 12 10 10 9.65 10 10 9.53 11 9.17
Selling, General & Admin Expense		 9.21 11 9.28 8.55 8.26 7.63 8.43 9.17 8.61 9.44 8.15
Research & Development Expense		 3.75 3.96 2.25 1.52 1.83 2.02 1.66 1.26 0.92 1.24 1.03
Total Other Income / (Expense), net		 -1.84 2.76 -1.43 -0.72 2.06 -5.86 2.41 5.56 -0.71 -1.11 -2.09
Interest & Investment Income		 -0.03 -0.05 -0.01 -0.18 -0.59 -0.62 -0.61 -0.62 -0.65 -0.75 -0.86
Other Income / (Expense), net		 -1.81 2.81 -1.43 -0.54 2.65 -5.24 3.01 6.18 -0.06 -0.37 -1.23
Basic Earnings per Share		 ($0.21) ($0.13) ($0.11) ($0.08) ($0.05) ($0.14) ($0.02) $0.03 ($0.05) ($0.09) ($0.08)
Weighted Average Basic Shares Outstanding		 44.37M 44.66M 54.43M 54.31M 54.45M 54.43M 60.73M 62.61M 62.75M 62.23M 62.74M
Diluted Earnings per Share		 ($0.21) ($0.13) ($0.11) ($0.08) ($0.05) ($0.14) ($0.02) $0.03 ($0.05) ($0.09) ($0.08)
Weighted Average Diluted Shares Outstanding		 44.37M 44.66M 54.43M 54.31M 54.45M 54.43M 60.73M 67.17M 62.75M 62.23M 62.74M
Weighted Average Basic & Diluted Shares Outstanding		 44.44M 54.29M 54.31M 54.43M 54.68M 62.50M 62.61M 62.76M 62.80M 62.70M 62.79M

Annual Cash Flow Statements for Cytosorbents

This table details how cash moves in and out of Cytosorbents' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 1.71 -0.07 12 5.05 -10 59 -18 -30 -8.22 -5.85 -1.99
Net Cash From Operating Activities		 -9.05 -6.73 -6.46 -11 -17 -5.61 -14 -28 -22 -14 -12
Net Cash From Continuing Operating Activities		 -9.05 -6.73 -6.46 -11 -17 -5.61 -14 -28 -22 -14 -12
Net Income / (Loss) Continuing Operations		 -9.48 -12 -8.46 -17 -19 -7.84 -25 -33 -29 -21 -8.20
Consolidated Net Income / (Loss)		 -9.48 -12 -8.46 -17 -19 -7.84 -25 -33 -29 -21 -8.20
Depreciation Expense		 0.11 0.16 0.22 0.39 0.58 0.66 0.73 0.88 1.46 1.34 1.23
Amortization Expense		 0.00 0.03 0.08 0.10 0.12 0.32 0.40 0.25 0.56 0.79 1.22
Non-Cash Adjustments To Reconcile Net Income		 -0.00 3.61 2.55 6.82 3.26 2.00 8.78 7.01 2.92 8.55 -5.60
Changes in Operating Assets and Liabilities, net		 0.28 1.23 -0.85 -0.94 -1.45 -0.76 0.64 -3.56 2.65 -4.38 -1.03
Net Cash From Investing Activities		 -0.89 1.60 -1.68 -1.52 -1.52 -1.68 -4.28 -6.46 -0.94 -0.67 -0.42
Net Cash From Continuing Investing Activities		 -0.89 1.60 -1.68 -1.52 -1.52 -1.68 -4.28 -6.46 -0.94 -0.67 -0.42
Purchase of Property, Plant & Equipment		 -0.40 -0.14 -0.99 -0.67 -0.70 -0.71 -3.64 -6.09 -0.54 -0.28 -0.16
Acquisitions		 -0.24 -0.45 -0.69 -0.85 -0.82 -0.97 -0.64 -0.37 -0.40 -0.39 -0.33
Sale of Property, Plant & Equipment		 - - - - - - - - - 0.00 0.08
Net Cash From Financing Activities		 12 5.06 20 17 8.18 66 0.72 4.96 14 9.33 9.31
Net Cash From Continuing Financing Activities		 12 5.06 20 17 8.18 66 0.72 4.96 14 9.33 9.31
Repayment of Debt		 0.00 -0.12 0.00 -0.67 -0.00 -16 - - 0.00 -5.70 0.00
Issuance of Debt		 - 5.00 5.00 0.67 5.00 1.41 0.00 5.00 0.00 15 2.48
Other Financing Activities, net		 12 0.18 15 17 3.18 81 0.72 -0.04 14 0.03 6.83
Effect of Exchange Rate Changes		 0.01 -0.00 0.09 -0.06 -0.04 0.13 -0.02 -0.26 -0.10 -0.09 1.49
Cash Interest Paid		 0.00 0.18 0.63 0.89 1.06 1.13 0.00 0.00 0.38 1.29 2.08

Quarterly Cash Flow Statements for Cytosorbents

This table details how cash moves in and out of Cytosorbents' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Change in Cash & Equivalents		 -4.79 5.57 -5.52 4.85 -2.78 -2.40 3.35 -1.38 -2.67 -1.29 -1.44
Net Cash From Operating Activities		 -5.21 -6.41 -4.83 -4.79 -2.46 -2.34 -3.47 -1.51 -2.58 -4.83 -1.16
Net Cash From Continuing Operating Activities		 -5.21 -6.41 -4.83 -4.79 -2.46 -2.34 -3.47 -1.51 -2.58 -4.83 -1.16
Net Income / (Loss) Continuing Operations		 -9.19 -6.57 -6.09 -4.30 -2.77 -7.57 -1.48 1.95 -3.17 -5.50 -5.13
Consolidated Net Income / (Loss)		 -9.19 -6.57 -6.09 -4.30 -2.77 -7.57 -1.48 1.95 -3.17 -5.50 -5.13
Depreciation Expense		 0.41 0.39 0.40 0.40 0.38 0.15 0.31 0.40 0.36 0.10 0.29
Amortization Expense		 0.06 0.40 0.05 0.05 0.24 0.46 0.29 0.23 0.23 0.54 0.38
Non-Cash Adjustments To Reconcile Net Income		 3.36 -0.98 2.49 1.82 -1.62 5.85 -2.19 -5.35 0.74 1.20 2.05
Changes in Operating Assets and Liabilities, net		 0.17 0.36 -1.67 -2.77 1.30 -1.24 -0.40 1.26 -0.73 -1.17 1.26
Net Cash From Investing Activities		 -0.26 -0.14 -0.13 -0.12 -0.30 -0.12 -0.05 -0.13 0.06 -0.29 -0.05
Net Cash From Continuing Investing Activities		 -0.26 -0.14 -0.13 -0.12 -0.30 -0.12 -0.05 -0.13 0.06 -0.29 -0.05
Purchase of Property, Plant & Equipment		 -0.14 -0.10 -0.05 -0.02 -0.15 -0.07 -0.00 -0.04 -0.02 -0.11 -0.01
Acquisitions		 -0.12 -0.04 -0.08 -0.10 -0.15 -0.06 -0.05 -0.09 0.07 -0.26 -0.06
Sale of Property, Plant & Equipment		 - - - - - - 0.00 - - - 0.03
Net Cash From Financing Activities		 0.65 12 -0.57 9.83 -0.10 0.17 6.83 -0.00 - 2.48 0.00
Net Cash From Continuing Financing Activities		 0.65 12 -0.57 9.83 -0.10 0.17 6.83 -0.00 - 2.48 0.00
Other Financing Activities, net		 0.65 12 0.05 -0.15 -0.04 0.17 6.83 -0.00 - - 0.00
Effect of Exchange Rate Changes		 0.02 -0.10 0.01 -0.07 0.09 -0.11 0.03 0.26 -0.15 1.35 -0.23
Cash Interest Paid		 0.10 0.10 0.20 0.34 0.23 0.52 0.51 0.51 0.52 0.55 0.59

Annual Balance Sheets for Cytosorbents

This table presents Cytosorbents' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 11 9.69 24 34 27 90 90 63 53 47 44
Total Current Assets		 9.86 7.83 21 28 21 82 64 34 25 22 21
Cash & Equivalents		 5.32 5.25 17 22 12 71 52 22 14 3.28 6.25
Accounts Receivable		 0.65 1.43 2.21 3.94 4.47 5.16 4.52 5.66 6.06 7.32 7.55
Inventories, net		 1.19 0.83 0.80 0.83 2.11 2.67 4.77 3.46 3.38 2.73 5.28
Prepaid Expenses		 0.51 0.32 0.42 1.12 2.09 3.20 2.87 2.49 1.83 3.27 1.55
Plant, Property, & Equipment, net		 0.56 0.57 1.40 1.73 1.93 2.12 5.15 11 10 9.00 7.82
Total Noncurrent Assets		 0.84 1.30 1.96 4.20 4.56 5.38 20 19 18 17 16
Intangible Assets		 - - - - - - - - - 3.72 3.23
Other Noncurrent Operating Assets		 0.84 1.30 1.96 4.20 4.56 5.38 20 19 18 13 12
Total Liabilities & Shareholders' Equity		 11 9.69 24 34 27 90 90 63 53 47 44
Total Liabilities		 3.04 8.36 14 17 24 11 27 28 29 36 38
Total Current Liabilities		 3.04 4.28 7.85 6.92 9.94 10 14 9.71 14 9.83 9.71
Short-Term Debt		 0.00 0.83 4.00 0.67 1.67 - - 0.00 2.50 - 0.00
Accounts Payable		 0.68 1.33 1.24 1.49 2.04 1.84 2.81 1.66 3.80 3.34 2.87
Accrued Expenses		 0.72 2.11 2.60 4.39 5.80 7.87 10 7.95 7.36 6.03 6.30
Other Current Liabilities		 1.64 - - 0.38 0.43 0.45 0.57 0.11 0.37 0.45 0.54
Total Noncurrent Liabilities		 0.00 4.08 5.99 10 14 0.58 13 18 15 26 29
Long-Term Debt		 0.00 4.08 5.99 9.27 13 - 0.00 5.00 2.54 14 17
Other Noncurrent Operating Liabilities		 - - - 1.07 0.64 0.58 13 13 13 12 12
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 8.21 1.34 10 17 3.42 79 63 35 23 11 5.90
Total Preferred & Common Equity		 8.21 1.34 10 17 3.42 79 63 35 23 11 5.90
Preferred Stock		 - - - - 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 8.21 1.34 10 17 3.42 79 63 35 23 11 5.90
Common Stock		 140 144 163 186 192 278 283 287 306 311 321
Retained Earnings		 -133 -144 -152 -170 -189 -197 -221 -254 -283 -304 -312
Accumulated Other Comprehensive Income / (Loss)		 0.58 0.90 -0.36 0.29 0.53 -1.73 0.53 2.33 0.53 4.25 -2.98

Quarterly Balance Sheets for Cytosorbents

This table presents Cytosorbents' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026
Period end date 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026
Total Assets		 48 47 53 48 51 48 46 41
Total Current Assets		 19 20 22 17 25 23 21 18
Cash & Equivalents		 8.36 8.61 8.46 5.69 12 10 7.54 4.81
Accounts Receivable		 6.18 6.77 7.82 6.63 7.67 7.74 7.43 7.15
Inventories, net		 2.98 3.74 4.32 3.25 3.02 3.71 4.00 4.48
Prepaid Expenses		 1.75 0.88 1.36 1.03 3.14 1.33 2.35 1.31
Plant, Property, & Equipment, net		 10 9.75 9.42 9.27 8.72 8.47 8.19 7.51
Total Noncurrent Assets		 18 17 22 22 17 17 16 15
Intangible Assets		 - - - - - - - 2.95
Other Noncurrent Operating Assets		 18 17 22 22 17 17 16 12
Total Liabilities & Shareholders' Equity		 48 47 53 48 51 48 46 41
Total Liabilities		 29 28 37 35 36 36 37 38
Total Current Liabilities		 12 13 10 8.43 9.74 9.84 10 16
Short-Term Debt		 0.83 2.50 0.00 0.00 - - - 6.65
Accounts Payable		 3.44 2.40 3.05 2.34 3.33 3.39 3.04 3.13
Accrued Expenses		 7.58 8.13 6.88 5.66 5.94 5.95 6.56 5.96
Other Current Liabilities		 0.12 0.39 0.41 0.43 0.47 0.50 0.52 0.57
Total Noncurrent Liabilities		 17 15 26 26 27 27 27 22
Long-Term Debt		 4.20 1.93 14 14 14 14 15 10
Other Noncurrent Operating Liabilities		 13 13 13 13 12 12 12 12
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 19 19 17 13 15 12 9.02 2.19
Total Preferred & Common Equity		 19 19 17 13 15 12 9.02 2.19
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 19 19 17 13 15 12 9.02 2.19
Common Stock		 292 306 308 308 319 319 320 322
Retained Earnings		 -277 -289 -293 -295 -305 -304 -307 -317
Accumulated Other Comprehensive Income / (Loss)		 2.98 1.75 2.17 -0.16 1.52 -3.96 -3.84 -2.10

Annual Metrics And Ratios for Cytosorbents

This table displays calculated financial ratios and metrics derived from Cytosorbents' official financial filings.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding		 25,365,673.00 25,468,966.00 28,691,325.00 31,651,821.00 32,423,763.00 43,175,685.00 43,475,648.00 43,635,715.00 44,438,509.00 54,679,569.00 62,804,305.00
DEI Adjusted Shares Outstanding		 25,365,673.00 25,468,966.00 28,691,325.00 31,651,821.00 32,423,763.00 43,175,685.00 43,475,648.00 43,635,715.00 44,438,509.00 54,679,569.00 62,804,305.00
DEI Earnings Per Adjusted Shares Outstanding		 -0.37 -0.46 -0.31 -0.54 -0.59 -0.18 -0.56 -0.75 -0.66 -0.38 -0.13
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 16.22% 98.84% 59.02% 48.53% 10.87% 64.35% 5.27% -19.64% -10.39% 14.51% 4.12%
EBITDA Growth		 -6.18% -20.21% 30.62% -96.36% -17.29% 63.60% -256.85% -36.01% 15.28% 32.26% 81.28%
EBIT Growth		 -4.40% -20.79% 29.21% -95.15% -18.05% 59.83% -226.19% -34.42% 12.15% 29.74% 71.51%
NOPAT Growth		 -34.98% -23.52% 14.35% -58.34% -21.75% 45.34% -119.33% -38.59% -1.35% 48.50% 10.35%
Net Income Growth		 -1.67% -24.13% 28.08% -103.42% -11.94% 59.32% -213.36% -33.61% 10.87% 29.16% 60.43%
EPS Growth		 70.54% -21.05% 30.43% -75.00% -7.14% 66.67% -185.00% -31.58% 13.33% 41.54% 65.79%
Operating Cash Flow Growth		 -44.05% 25.61% 4.02% -67.78% -54.61% 66.51% -149.51% -101.59% 23.30% 33.37% 14.22%
Free Cash Flow Firm Growth		 51.22% 5.16% -5.66% -41.55% -20.26% 41.28% -110.63% -60.79% 37.95% 24.72% 29.57%
Invested Capital Growth		 144.23% 43.06% 192.16% 53.66% 38.40% 24.95% 33.96% 74.61% -21.05% 16.88% -2.98%
Revenue Q/Q Growth		 22.73% 16.12% 11.50% 6.81% 5.72% 12.41% -2.65% -3.86% -16.15% 19.25% 0.23%
EBITDA Q/Q Growth		 15.28% -11.77% 14.53% -15.90% 5.78% 33.82% -53.00% 19.18% -21.39% -8.46% 52.46%
EBIT Q/Q Growth		 14.84% -11.90% 13.95% -15.96% 5.37% 29.74% -51.53% 19.30% -22.15% -6.59% 39.35%
NOPAT Q/Q Growth		 2.40% -19.90% 7.21% -12.89% 0.80% 21.24% -43.80% 9.23% -13.46% 29.10% -4.65%
Net Income Q/Q Growth		 14.81% -13.36% 15.79% -15.09% 7.02% 29.45% -54.17% 20.65% -24.78% -5.04% 20.17%
EPS Q/Q Growth		 42.42% -12.20% 11.11% -7.69% 6.25% 39.39% -58.33% 21.05% -22.64% -2.70% 27.78%
Operating Cash Flow Q/Q Growth		 -1.50% 14.55% 9.39% -26.90% -9.24% 35.33% -46.32% 0.53% -5.18% 21.99% -25.11%
Free Cash Flow Firm Q/Q Growth		 65.18% -26.80% 23.75% -16.66% -6.59% 18.82% -40.39% 4.71% -1.21% 37.12% -104.76%
Invested Capital Q/Q Growth		 2,512.28% 1,105.00% -27.39% -11.23% 8.07% 5.12% 9.12% 9.89% -5.21% -20.34% 1.68%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 53.82% 58.50% 63.58% 66.72% 70.48% 73.05% 74.41% 59.77% 70.62% 69.92% 71.48%
EBITDA Margin		 -202.39% -122.36% -53.38% -70.57% -74.66% -16.53% -56.05% -94.86% -89.69% -53.06% -9.54%
Operating Margin		 -194.17% -120.62% -64.96% -69.25% -76.05% -25.29% -52.69% -90.87% -102.78% -46.22% -39.79%
EBIT Margin		 -204.75% -124.37% -55.37% -72.74% -77.45% -18.93% -58.66% -98.12% -96.20% -59.03% -16.15%
Profit (Net Income) Margin		 -197.78% -123.46% -55.84% -76.48% -77.22% -19.11% -56.89% -94.59% -94.09% -58.21% -22.12%
Tax Burden Percent		 96.69% 97.36% 92.59% 96.53% 94.63% 87.43% 97.09% 96.78% 97.29% 92.45% 95.34%
Interest Burden Percent		 99.91% 101.96% 108.93% 108.93% 105.35% 115.47% 99.89% 99.61% 100.53% 106.66% 143.63%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% -943.27% -350.00% -293.26% -247.22% -103.47% -174.63% -153.92% -137.10% -73.79% -62.30%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% -848.42% -309.00% -229.47% -122.66% -101.78% -160.65% -122.90% -84.63% 471.99% -35.94%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 696.86% 204.13% 166.70% 57.91% 84.50% 139.99% 86.92% 37.72% -46.02% -34.09%
Return on Equity (ROE)		 -155.70% -246.41% -145.87% -126.56% -189.32% -18.97% -34.64% -67.00% -99.38% -119.80% -96.39%
Cash Return on Invested Capital (CROIC)		 -1,254.17% -978.70% -448.00% -335.57% -279.44% -125.65% -203.66% -208.26% -113.58% -89.35% -59.27%
Operating Return on Assets (OROA)		 -99.49% -113.14% -49.64% -56.16% -62.76% -13.23% -28.22% -44.57% -51.47% -41.88% -13.08%
Return on Assets (ROA)		 -96.10% -112.31% -50.07% -59.04% -62.57% -13.36% -27.37% -42.96% -50.34% -41.30% -17.91%
Return on Common Equity (ROCE)		 -155.70% -246.41% -145.87% -126.56% -189.32% -18.97% -34.64% -67.00% -99.38% -119.80% -96.39%
Return on Equity Simple (ROE_SIMPLE)		 -115.42% -879.54% -82.44% -101.63% -563.65% -9.89% -39.24% -92.76% -124.55% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -6.51 -8.04 -6.89 -11 -13 -7.26 -16 -22 -22 -12 -10
NOPAT Margin		 -135.92% -84.43% -45.48% -48.48% -53.24% -17.70% -36.88% -63.61% -71.94% -32.35% -27.86%
Net Nonoperating Expense Percent (NNEP)		 -45.40% -94.84% -41.00% -63.79% -124.56% -1.69% -13.98% -31.02% -52.47% -545.78% -26.36%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - - - - - -78.40% -45.88% -45.74%
Cost of Revenue to Revenue		 46.18% 41.50% 36.42% 33.28% 29.52% 26.95% 25.59% 40.23% 29.38% 30.08% 28.52%
SG&A Expenses to Revenue		 167.20% 136.37% 107.28% 101.66% 98.07% 76.85% 89.15% 107.05% 123.23% 94.77% 96.17%
R&D to Revenue		 80.79% 42.75% 21.26% 34.32% 48.47% 21.49% 37.95% 43.58% 50.17% 21.37% 13.72%
Operating Expenses to Revenue		 247.99% 179.12% 128.54% 135.97% 146.53% 98.34% 127.10% 150.64% 173.40% 116.14% 111.27%
Earnings before Interest and Taxes (EBIT)		 -9.81 -12 -8.39 -16 -19 -7.76 -25 -34 -30 -21 -5.99
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -9.70 -12 -8.09 -16 -19 -6.78 -24 -33 -28 -19 -3.54
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 17.21 103.78 18.17 15.10 36.52 4.34 2.91 1.91 2.10 4.48 6.80
Price to Tangible Book Value (P/TBV)		 17.21 103.78 18.17 15.10 36.52 4.34 2.91 1.91 2.10 6.74 15.00
Price to Revenue (P/Rev)		 29.49 14.57 12.31 11.36 5.00 8.39 4.22 1.95 1.59 1.40 1.08
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 190.64 137.93 61.08 53.99 20.46 34.99 12.45 2.77 2.80 3.30 3.10
Enterprise Value to Revenue (EV/Rev)		 27.92 14.53 11.83 10.81 5.12 6.65 3.01 1.46 1.29 1.56 1.36
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.00 3.67 0.97 0.59 4.40 0.00 0.00 0.14 0.21 1.26 2.82
Long-Term Debt to Equity		 0.00 3.05 0.58 0.55 3.92 0.00 0.00 0.14 0.11 1.26 2.82
Financial Leverage		 -1.07 -0.82 -0.66 -0.73 -0.47 -0.83 -0.87 -0.71 -0.45 -0.10 0.95
Leverage Ratio		 1.62 2.19 2.91 2.14 3.03 1.42 1.27 1.56 1.97 2.90 5.38
Compound Leverage Factor		 1.62 2.24 3.17 2.33 3.19 1.64 1.26 1.55 1.98 3.09 7.73
Debt to Total Capital		 0.00% 78.60% 49.33% 36.99% 81.49% 0.00% 0.00% 12.38% 17.68% 55.75% 73.85%
Short-Term Debt to Total Capital		 0.00% 13.34% 19.75% 2.48% 9.02% 0.00% 0.00% 0.00% 8.76% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 65.26% 29.58% 34.51% 72.47% 0.00% 0.00% 12.38% 8.91% 55.75% 73.85%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 100.00% 21.40% 50.67% 63.01% 18.51% 100.00% 100.00% 87.62% 82.32% 44.25% 26.15%
Debt to EBITDA		 0.00 -0.42 -1.24 -0.63 -0.81 0.00 0.00 -0.15 -0.18 -0.74 -4.71
Net Debt to EBITDA		 0.00 0.03 0.91 0.78 -0.15 0.00 0.00 0.52 0.33 -0.30 -2.95
Long-Term Debt to EBITDA		 0.00 -0.35 -0.74 -0.58 -0.72 0.00 0.00 -0.15 -0.09 -0.74 -4.71
Debt to NOPAT		 0.00 -0.61 -1.45 -0.91 -1.13 0.00 0.00 -0.23 -0.23 -1.22 -1.61
Net Debt to NOPAT		 0.00 0.04 1.06 1.14 -0.21 0.00 0.00 0.78 0.41 -0.50 -1.01
Long-Term Debt to NOPAT		 0.00 -0.51 -0.87 -0.85 -1.01 0.00 0.00 -0.23 -0.11 -1.22 -1.61
Altman Z-Score		 9.64 -13.37 -0.64 1.78 -7.46 17.31 0.82 -4.94 -7.50 -8.58 -8.58
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 3.24 1.83 2.64 4.09 2.10 8.12 4.70 3.48 1.81 2.20 2.13
Quick Ratio		 2.68 1.56 2.49 3.80 1.68 7.54 4.14 2.86 1.44 1.08 1.42
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -8.80 -8.35 -8.82 -12 -15 -8.82 -19 -30 -19 -14 -9.82
Operating Cash Flow to CapEx		 -2,241.72% -4,783.10% -652.15% -1,613.12% -2,400.40% -792.39% -384.64% -463.82% -4,024.26% -5,080.28% -14,064.77%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.49 0.91 0.90 0.77 0.81 0.70 0.48 0.45 0.54 0.71 0.81
Accounts Receivable Turnover		 6.53 9.15 8.33 7.32 5.93 8.52 8.92 6.81 5.30 5.32 4.98
Inventory Turnover		 2.56 3.91 6.77 9.20 5.00 4.62 2.97 3.39 2.67 3.51 2.64
Fixed Asset Turnover		 11.93 16.91 15.36 14.37 13.65 20.27 11.87 4.37 2.99 3.74 4.41
Accounts Payable Turnover		 3.20 3.92 4.29 5.49 4.18 5.71 4.76 6.26 3.35 3.00 3.41
Days Sales Outstanding (DSO)		 55.91 39.89 43.84 49.87 61.52 42.84 40.94 53.60 68.82 68.59 73.22
Days Inventory Outstanding (DIO)		 142.55 93.46 53.89 39.69 73.04 79.06 122.91 107.59 136.65 104.11 138.34
Days Payable Outstanding (DPO)		 114.07 93.00 85.14 66.53 87.36 63.97 76.66 58.33 109.07 121.73 107.18
Cash Conversion Cycle (CCC)		 84.40 40.35 12.59 23.03 47.19 57.93 87.19 102.87 96.40 50.97 104.38
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 0.70 1.00 2.93 4.51 6.24 7.79 10 18 14 17 16
Invested Capital Turnover		 -10.83 11.17 7.70 6.05 4.64 5.84 4.73 2.42 1.91 2.28 2.24
Increase / (Decrease) in Invested Capital		 2.29 0.30 1.93 1.57 1.73 1.56 2.65 7.79 -3.84 2.43 -0.50
Enterprise Value (EV)		 134 138 179 243 128 273 130 50 40 55 51
Market Capitalization		 141 139 186 256 125 344 182 68 49 50 40
Book Value per Share		 $0.32 $0.05 $0.36 $0.54 $0.11 $1.83 $1.44 $0.81 $0.53 $0.20 $0.09
Tangible Book Value per Share		 $0.32 $0.05 $0.36 $0.54 $0.11 $1.83 $1.44 $0.81 $0.53 $0.14 $0.04
Total Capital		 8.21 6.25 20 27 18 79 63 40 29 25 23
Total Debt		 0.00 4.91 9.99 9.94 15 0.00 0.00 5.00 5.04 14 17
Total Long-Term Debt		 0.00 4.08 5.99 9.27 13 0.00 0.00 5.00 2.54 14 17
Net Debt		 -7.51 -0.33 -7.33 -12 2.82 -71 -52 -17 -9.09 5.72 10
Capital Expenditures (CapEx)		 0.40 0.14 0.99 0.67 0.70 0.71 3.64 6.09 0.54 0.28 0.09
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -0.69 -0.86 -0.43 -0.35 0.40 0.88 -1.53 1.90 -0.27 3.50 4.68
Debt-free Net Working Capital (DFNWC)		 6.82 4.38 17 22 13 72 51 24 14 12 11
Net Working Capital (NWC)		 6.82 3.55 13 21 11 72 51 24 11 12 11
Net Nonoperating Expense (NNE)		 2.96 3.72 1.57 6.30 5.98 0.58 8.64 11 6.88 9.20 -2.13
Net Nonoperating Obligations (NNO)		 -7.51 -0.33 -7.33 -12 2.82 -71 -52 -17 -9.09 5.72 10
Total Depreciation and Amortization (D&A)		 0.11 0.19 0.30 0.49 0.70 0.98 1.13 1.13 2.02 2.13 2.45
Debt-free, Cash-free Net Working Capital to Revenue		 -14.45% -9.04% -2.84% -1.58% 1.60% 2.14% -3.54% 5.48% -0.86% 9.83% 12.62%
Debt-free Net Working Capital to Revenue		 142.26% 46.01% 111.49% 97.82% 50.63% 176.32% 117.24% 69.32% 44.60% 33.09% 29.48%
Net Working Capital to Revenue		 142.26% 37.26% 85.08% 94.86% 43.95% 176.32% 117.24% 69.32% 36.55% 33.09% 29.48%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.33) ($0.47) ($0.32) ($0.56) ($0.60) ($0.20) ($0.57) ($0.75) ($0.64) ($0.38) ($0.13)
Adjusted Weighted Average Basic Shares Outstanding		 25.41M 25.52M 29.47M 31.86M 35.05M 43.26M 43.36M 43.57M 44.66M 54.43M 62.23M
Adjusted Diluted Earnings per Share		 ($0.33) ($0.47) ($0.32) ($0.56) ($0.60) ($0.20) ($0.57) ($0.75) ($0.64) ($0.38) ($0.13)
Adjusted Weighted Average Diluted Shares Outstanding		 25.41M 25.52M 29.47M 31.86M 35.05M 43.26M 43.36M 43.57M 44.66M 54.43M 62.23M
Adjusted Basic & Diluted Earnings per Share		 ($0.33) ($0.47) ($0.32) ($0.56) ($0.60) ($0.20) $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 24.89M 25.43M 27.61M 30.72M 32.26M 38.82M 43.51M 43.66M 54.29M 62.50M 62.70M
Normalized Net Operating Profit after Tax (NOPAT)		 -6.51 -8.04 -6.89 -11 -13 -7.26 -16 -22 -22 -12 -9.97
Normalized NOPAT Margin		 -135.92% -84.43% -45.48% -48.48% -53.24% -17.70% -36.88% -63.61% -71.94% -32.35% -26.89%
Pre Tax Income Margin		 -204.56% -126.81% -60.31% -79.23% -81.60% -21.86% -58.60% -97.74% -96.70% -62.96% -23.20%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Quarterly Metrics And Ratios for Cytosorbents

This table displays calculated financial ratios and metrics derived from Cytosorbents' official financial filings.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
DEI Shares Outstanding		 44,362,386.00 44,438,509.00 54,293,555.00 54,306,415.00 54,429,617.00 54,679,569.00 62,500,000.00 62,610,376.00 62,761,805.00 62,804,305.00 62,700,000.00
DEI Adjusted Shares Outstanding		 44,362,386.00 44,438,509.00 54,293,555.00 54,306,415.00 54,429,617.00 54,679,569.00 62,500,000.00 62,610,376.00 62,761,805.00 62,804,305.00 62,700,000.00
DEI Earnings Per Adjusted Shares Outstanding		 -0.21 -0.15 -0.11 -0.08 -0.05 -0.14 -0.02 0.03 -0.05 -0.09 -0.08
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 8.62% -63.75% -4.87% -6.14% -2.25% 168.83% -2.92% 8.77% 10.12% 0.91% 1.57%
EBITDA Growth		 27.34% -300.69% 18.85% 35.51% 82.05% -22.49% 95.05% 187.09% -49.58% 48.66% -1,192.11%
EBIT Growth		 25.21% -283.58% 16.26% 33.04% 76.20% -17.71% 85.63% 162.30% -34.22% 44.98% -388.79%
NOPAT Growth		 18.49% -59.64% 41.00% 45.57% 34.29% 66.54% 16.50% -44.66% 40.75% -29.13% 21.71%
Net Income Growth		 24.65% -758.12% 16.89% 30.21% 69.89% -15.12% 75.71% 145.34% -14.52% 27.37% -246.79%
EPS Growth		 25.00% -1,200.00% 35.29% 42.86% 76.19% -7.69% 81.82% 137.50% 0.00% 35.71% -300.00%
Operating Cash Flow Growth		 22.70% -19.98% -55.39% 30.85% 52.69% 63.46% 28.24% 68.50% -4.63% -106.11% 66.47%
Free Cash Flow Firm Growth		 71.95% 73.32% 61.55% -168.50% -149.05% -47.19% -65.57% 130.37% 132.90% 46.59% 113.12%
Invested Capital Growth		 -8.47% -21.05% -1.14% 37.50% 39.09% 16.88% 16.23% -28.21% -24.00% -2.98% -16.35%
Revenue Q/Q Growth		 -6.47% -61.37% 164.10% -1.64% -2.59% 6.24% -4.63% 10.20% -1.37% -2.65% -4.00%
EBITDA Q/Q Growth		 -52.94% 24.73% 13.86% 34.97% 57.43% -413.71% 96.52% 1,248.42% -173.11% -76.31% 12.43%
EBIT Q/Q Growth		 -49.08% 19.91% 17.09% 32.36% 47.01% -296.10% 89.88% 393.51% -214.16% -62.36% 10.08%
NOPAT Q/Q Growth		 -12.06% -38.06% 54.11% 23.33% -35.29% 29.70% -14.50% -32.85% 44.58% -53.21% 30.58%
Net Income Q/Q Growth		 -49.41% 28.49% 7.39% 29.48% 35.54% -173.42% 80.46% 231.70% -262.81% -73.40% 6.69%
EPS Q/Q Growth		 -50.00% 38.10% 15.38% 27.27% 37.50% -180.00% 85.71% 250.00% -266.67% -80.00% 11.11%
Operating Cash Flow Q/Q Growth		 24.91% -23.07% 24.62% 0.74% 48.63% 4.95% -48.06% 56.42% -70.66% -87.23% 75.92%
Free Cash Flow Firm Q/Q Growth		 -18.36% 12.69% 5.39% -174.63% -9.79% 48.40% -6.42% 150.38% 18.95% -183.75% 126.15%
Invested Capital Q/Q Growth		 -4.89% -5.21% 2.47% 48.84% -3.79% -20.34% 1.90% -8.07% 1.85% 1.68% -12.14%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 63.64% 143.15% 76.46% 73.55% 61.02% 68.35% 71.12% 70.85% 70.28% 73.68% 69.16%
EBITDA Margin		 -98.71% -192.33% -62.73% -41.47% -18.12% -87.63% -3.20% 33.21% -24.62% -44.58% -40.67%
Operating Margin		 -83.42% -298.13% -51.80% -40.38% -56.08% -37.11% -44.55% -37.59% -30.17% -47.49% -34.34%
EBIT Margin		 -103.96% -215.52% -67.66% -46.53% -25.31% -94.37% -10.01% 26.65% -30.85% -51.45% -48.19%
Profit (Net Income) Margin		 -104.34% -193.15% -67.73% -48.56% -32.14% -82.71% -16.95% 20.25% -33.42% -59.53% -57.86%
Tax Burden Percent		 100.00% 88.99% 100.00% 100.00% 100.00% 81.74% 100.00% 100.00% 88.77% 100.00% 100.00%
Interest Burden Percent		 100.37% 100.71% 100.11% 104.38% 126.97% 107.23% 169.22% 75.97% 122.04% 115.70% 120.06%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 -136.26% -397.69% -74.86% -44.79% -64.55% -59.24% -69.10% -71.98% -42.03% -74.34% -56.81%
ROIC Less NNEP Spread (ROIC-NNEP)		 -104.98% -401.73% -43.80% 78.34% -38.97% 248.64% -226.36% 46.51% -57.42% -104.43% -97.48%
Return on Net Nonoperating Assets (RNNOA)		 47.12% 179.05% 16.66% -5.59% -5.93% -24.24% 10.69% 15.42% -39.51% -99.05% -85.88%
Return on Equity (ROE)		 -89.14% -218.64% -58.20% -50.39% -70.48% -83.48% -58.42% -56.57% -81.54% -173.39% -142.69%
Cash Return on Invested Capital (CROIC)		 -115.22% -113.58% -134.36% -126.56% -122.18% -89.35% -83.87% -26.79% -25.81% -59.27% -44.03%
Operating Return on Assets (OROA)		 -70.17% -115.32% -39.64% -26.41% -15.84% -66.96% -7.23% 18.98% -24.39% -41.66% -39.26%
Return on Assets (ROA)		 -70.43% -103.35% -39.69% -27.56% -20.11% -58.69% -12.24% 14.42% -26.42% -48.20% -47.13%
Return on Common Equity (ROCE)		 -89.14% -218.64% -58.20% -50.39% -70.48% -83.48% -58.42% -56.57% -81.54% -173.39% -142.69%
Return on Equity Simple (ROE_SIMPLE)		 -126.62% 0.00% -147.98% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -5.15 -7.10 -3.26 -2.50 -3.38 -2.38 -2.72 -3.62 -2.00 -3.07 -2.13
NOPAT Margin		 -58.40% -208.69% -36.26% -28.26% -39.25% -25.98% -31.19% -37.59% -21.12% -33.24% -24.04%
Net Nonoperating Expense Percent (NNEP)		 -31.29% 4.03% -31.06% -123.13% -25.58% -307.88% 157.25% -118.50% 15.40% 30.09% 40.67%
Return On Investment Capital (ROIC_SIMPLE)		 - -24.90% -13.96% -8.22% -12.61% -9.47% -9.47% -13.92% -8.49% -13.60% -11.13%
Cost of Revenue to Revenue		 36.36% -43.15% 23.54% 26.45% 38.98% 31.65% 28.88% 29.15% 29.72% 26.32% 30.84%
SG&A Expenses to Revenue		 104.51% 324.87% 103.27% 96.74% 95.90% 83.44% 96.62% 95.32% 90.77% 102.19% 91.93%
R&D to Revenue		 42.55% 116.40% 24.99% 17.18% 21.20% 22.02% 19.06% 13.12% 9.68% 13.45% 11.56%
Operating Expenses to Revenue		 147.06% 441.28% 128.26% 113.92% 117.10% 105.46% 115.68% 108.44% 100.45% 121.17% 103.50%
Earnings before Interest and Taxes (EBIT)		 -9.16 -7.34 -6.08 -4.11 -2.18 -8.63 -0.87 2.56 -2.93 -4.75 -4.27
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -8.70 -6.55 -5.64 -3.67 -1.56 -8.02 -0.28 3.19 -2.34 -4.12 -3.61
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 4.51 2.10 2.73 2.28 6.28 4.48 4.30 6.92 6.50 6.80 16.18
Price to Tangible Book Value (P/TBV)		 4.51 2.10 2.73 2.28 6.28 6.74 4.30 6.92 6.50 15.00 0.00
Price to Revenue (P/Rev)		 2.25 1.59 1.68 1.27 2.74 1.40 1.77 2.22 1.59 1.08 0.95
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 5.27 2.80 3.21 1.98 4.25 3.30 3.80 5.35 4.09 3.10 3.32
Enterprise Value to Revenue (EV/Rev)		 2.16 1.29 1.55 1.44 3.01 1.56 1.84 2.34 1.78 1.36 1.28
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.27 0.21 0.23 0.82 1.06 1.26 0.98 1.24 1.62 2.82 7.73
Long-Term Debt to Equity		 0.23 0.11 0.10 0.82 1.06 1.26 0.98 1.24 1.62 2.82 4.70
Financial Leverage		 -0.45 -0.45 -0.38 -0.07 0.15 -0.10 -0.05 0.33 0.69 0.95 0.88
Leverage Ratio		 1.91 1.97 2.18 2.59 3.03 2.90 2.92 3.58 4.25 5.38 5.46
Compound Leverage Factor		 1.91 1.99 2.19 2.71 3.84 3.11 4.95 2.72 5.19 6.23 6.55
Debt to Total Capital		 21.37% 17.68% 18.96% 44.96% 51.51% 55.75% 49.38% 55.38% 61.76% 73.85% 88.54%
Short-Term Debt to Total Capital		 3.54% 8.76% 10.70% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 34.70%
Long-Term Debt to Total Capital		 17.83% 8.91% 8.26% 44.96% 51.51% 55.75% 49.38% 55.38% 61.76% 73.85% 53.85%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 78.63% 82.32% 81.04% 55.04% 48.49% 44.25% 50.62% 44.63% 38.24% 26.15% 11.46%
Debt to EBITDA		 -0.22 -0.18 -0.17 -0.56 -0.79 -0.74 -1.05 -2.16 -1.96 -4.71 -2.47
Net Debt to EBITDA		 0.14 0.33 0.16 -0.21 -0.47 -0.30 -0.19 -0.63 -0.95 -2.95 -1.77
Long-Term Debt to EBITDA		 -0.18 -0.09 -0.07 -0.56 -0.79 -0.74 -1.05 -2.16 -1.96 -4.71 -1.50
Debt to NOPAT		 -0.26 -0.23 -0.22 -0.76 -0.85 -1.22 -1.29 -1.28 -1.48 -1.61 -1.74
Net Debt to NOPAT		 0.17 0.41 0.21 -0.29 -0.50 -0.50 -0.24 -0.37 -0.71 -1.01 -1.25
Long-Term Debt to NOPAT		 -0.21 -0.11 -0.10 -0.76 -0.85 -1.22 -1.29 -1.28 -1.48 -1.61 -1.06
Altman Z-Score		 -6.09 -6.10 -7.10 -6.48 -6.56 -7.71 -6.38 -6.28 -7.54 -8.48 -9.79
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 1.61 1.81 1.49 2.12 1.97 2.20 2.61 2.34 2.11 2.13 1.09
Quick Ratio		 1.21 1.44 1.15 1.58 1.46 1.08 1.98 1.82 1.48 1.42 0.73
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -3.74 -3.27 -3.09 -8.49 -9.32 -4.81 -5.12 2.58 3.07 -2.57 0.67
Operating Cash Flow to CapEx		 -3,656.14% -6,709.54% -10,687.44% -26,920.33% -1,620.39% -3,392.75% -173,300.00% -4,094.59% -15,158.82% -4,467.59% 0.00%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.68 0.54 0.59 0.57 0.63 0.71 0.72 0.71 0.79 0.81 0.81
Accounts Receivable Turnover		 6.66 5.30 4.98 4.05 4.66 5.32 4.90 4.64 5.26 4.98 5.02
Inventory Turnover		 4.37 2.67 2.65 1.95 2.04 3.51 3.29 2.82 2.98 2.64 2.88
Fixed Asset Turnover		 3.53 2.99 3.00 3.02 3.05 3.74 3.83 4.04 4.24 4.41 4.58
Accounts Payable Turnover		 4.92 3.35 2.69 2.10 2.20 3.00 3.88 3.52 4.02 3.41 3.34
Days Sales Outstanding (DSO)		 54.84 68.82 73.26 90.18 78.33 68.59 74.56 78.68 69.39 73.22 72.72
Days Inventory Outstanding (DIO)		 83.58 136.65 137.49 187.59 179.10 104.11 110.98 129.22 122.53 138.34 126.89
Days Payable Outstanding (DPO)		 74.23 109.07 135.72 173.45 166.29 121.73 94.02 103.69 90.81 107.18 109.26
Cash Conversion Cycle (CCC)		 64.19 96.40 75.02 104.33 91.14 50.97 91.52 104.20 101.10 104.38 90.35
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 15 14 15 22 21 17 17 16 16 16 14
Invested Capital Turnover		 2.33 1.91 2.06 1.58 1.64 2.28 2.22 1.92 1.99 2.24 2.36
Increase / (Decrease) in Invested Capital		 -1.40 -3.84 -0.17 5.99 5.94 2.43 2.39 -6.19 -5.07 -0.50 -2.80
Enterprise Value (EV)		 80 40 47 43 90 55 65 84 66 51 48
Market Capitalization		 83 49 52 38 82 50 63 80 59 40 36
Book Value per Share		 $0.42 $0.53 $0.35 $0.31 $0.24 $0.20 $0.27 $0.19 $0.14 $0.09 $0.04
Tangible Book Value per Share		 $0.42 $0.53 $0.35 $0.31 $0.24 $0.14 $0.27 $0.19 $0.14 $0.04 ($0.01)
Total Capital		 24 29 23 30 27 25 29 26 24 23 19
Total Debt		 5.03 5.04 4.43 14 14 14 14 14 15 17 17
Total Long-Term Debt		 4.20 2.54 1.93 14 14 14 14 14 15 17 10
Net Debt		 -3.33 -9.09 -4.18 5.21 8.12 5.72 2.60 4.17 7.03 10 12
Capital Expenditures (CapEx)		 0.14 0.10 0.05 0.02 0.15 0.07 0.00 0.04 0.02 0.11 -0.02
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -0.24 -0.27 0.46 3.16 2.48 3.50 4.09 2.94 3.67 4.68 3.29
Debt-free Net Working Capital (DFNWC)		 8.12 14 9.07 12 8.17 12 16 13 11 11 8.10
Net Working Capital (NWC)		 7.29 11 6.57 12 8.17 12 16 13 11 11 1.45
Net Nonoperating Expense (NNE)		 4.05 -0.53 2.83 1.80 -0.61 5.19 -1.24 -5.56 1.17 2.43 3.00
Net Nonoperating Obligations (NNO)		 -3.33 -9.09 -4.18 5.21 8.12 5.72 2.60 4.17 7.03 10 12
Total Depreciation and Amortization (D&A)		 0.46 0.79 0.44 0.45 0.62 0.62 0.60 0.63 0.59 0.63 0.67
Debt-free, Cash-free Net Working Capital to Revenue		 -0.64% -0.86% 1.50% 10.52% 8.31% 9.83% 11.57% 8.15% 9.91% 12.62% 8.84%
Debt-free Net Working Capital to Revenue		 21.91% 44.60% 29.61% 38.67% 27.36% 33.09% 44.37% 36.41% 30.29% 29.48% 21.77%
Net Working Capital to Revenue		 19.66% 36.55% 21.45% 38.67% 27.36% 33.09% 44.37% 36.41% 30.29% 29.48% 3.91%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.21) ($0.13) ($0.12) ($0.08) ($0.04) ($0.14) ($0.02) $0.03 ($0.05) ($0.09) ($0.08)
Adjusted Weighted Average Basic Shares Outstanding		 44.37M 44.66M 54.26M 54.31M 54.45M 54.43M 60.73M 62.61M 62.75M 62.23M 62.74M
Adjusted Diluted Earnings per Share		 ($0.21) ($0.13) ($0.12) ($0.08) ($0.04) ($0.14) ($0.02) $0.03 ($0.05) ($0.09) ($0.08)
Adjusted Weighted Average Diluted Shares Outstanding		 44.37M 44.66M 54.26M 54.31M 54.45M 54.43M 60.73M 67.17M 62.75M 62.23M 62.74M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 44.44M 54.29M 54.31M 54.43M 54.68M 62.50M 62.61M 62.76M 62.80M 62.70M 62.79M
Normalized Net Operating Profit after Tax (NOPAT)		 -5.15 -7.10 -3.26 -2.50 -3.38 -2.38 -2.72 -2.53 -2.00 -3.07 -2.13
Normalized NOPAT Margin		 -58.40% -208.69% -36.26% -28.26% -39.25% -25.98% -31.19% -26.31% -21.12% -33.24% -24.04%
Pre Tax Income Margin		 -104.34% -217.05% -67.73% -48.56% -32.14% -101.19% -16.95% 20.25% -37.65% -59.53% -57.86%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Financials Breakdown Chart

Cytosorbents Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Cytosorbents' fiscal year ends in December. Their fiscal year 2025 ended on December 31, 2025.

Cytosorbents' net income appears to be on an upward trend, with a most recent value of -$8.20 million in 2025, falling from -$9.48 million in 2015. The previous period was -$20.72 million in 2024. Find out what analysts predict for Cytosorbents in the coming months.

Cytosorbents' total operating income in 2025 was -$14.75 million, based on the following breakdown:
  • Total Gross Profit: $26.49 million
  • Total Operating Expenses: $41.24 million

Over the last 10 years, Cytosorbents' total revenue changed from $4.79 million in 2015 to $37.06 million in 2025, a change of 673.5%.

Cytosorbents' total liabilities were at $38.28 million at the end of 2025, a 5.6% increase from 2024, and a 1,157.6% increase since 2015.

In the past 10 years, Cytosorbents' cash and equivalents has ranged from $3.28 million in 2024 to $71.42 million in 2020, and is currently $6.25 million as of their latest financial filing in 2025.

Over the last 10 years, Cytosorbents' book value per share changed from 0.32 in 2015 to 0.09 in 2025, a change of -71.0%.


Related Companies

Financial statements for NASDAQ:CTSO last updated on 7/16/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Buy this stock tomorrow
Marc Chaikin, founder of Chaikin Analytics, is flagging a little-known company that just secured a partnership...
Chaikin Analytics | Sponsoredtc pixel
Your withdrawal order could cost you in taxes
If you have $2M or more saved, the 4% rule points to roughly $92,000 a year - but it's a single-variable answe...
SmartAsset | Sponsoredtc pixel
#1 Question to Ask Your Bank Today
Elon Musk's new banking platform is paying up to 15 times the national average interest rate while insuring de...
InvestorPlace | Sponsoredtc pixel
Print this and keep it by your screen
Ever been right about a stock's direction and still lost money on the trade? It's almost never bad luck - it's...
Profits Run | Sponsoredtc pixel
AI investors should get ready for a BIG surprise
Wall Street insider Jason Bodner - who called Nvidia at $4.50 - says today's most popular AI stocks are about ...
Brownstone Research | Sponsoredtc pixel
URGENT Dollar Reset Warning for Monday
A 50-year U.S.-Saudi arrangement established under Henry Kissinger - one credited with anchoring the dollar in...
Golden Portfolio | Sponsoredtc pixel
SPCX Warning - and Worst News for Stocks in 50 Years
Goldman Sachs and Morgan Stanley are now predicting what could be the worst news for the U.S. stock market in ...
TradeSmith | Sponsoredtc pixel